Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF

Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF

ObjectiveThis study sought to identify key prognostic factors in patients with hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), emphasizing the prognostic role of free triiodothyronine (FT3) levels.Research design and methodsThis retrospective cohort stud...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhen-Yu Yang, Zhi-Yuan Zhang, Wei-Jie Zhang, Da Liu, Fu-Shi Piao, Xiangyu Yan, Fang-Tao Shi, Min Yang, Jing Chen, Sheng-song Zhu, Hong-Hou He, Pei-Hong Wu, Cheng Qian, Min Lin, Jun-Qing Feng, Chun-jin Lai
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
HCM-HFpEF
prognosis
FT3
thyroid function
all-cause mortality
cardiac transplantation
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2025.1546309/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectiveThis study sought to identify key prognostic factors in patients with hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), emphasizing the prognostic role of free triiodothyronine (FT3) levels.Research design and methodsThis retrospective cohort study enrolled 992 HCM-HFpEF patients from two Chinese medical centers between 2009 and 2019, excluding those with thyroid-affecting medications or disorders. Data on demographic and clinical variables, including FT3, were analyzed using univariate and multivariate Cox regression, Kaplan–Meier (KM) survival analysis, and restricted cubic spline (RCS) analysis to explore prognostic factors and FT3's nonlinear predictive value.ResultsAge, atrial fibrillation, and NT-proBNP levels significantly influenced prognosis, while FT3 emerged as an independent predictor of all-cause mortality and cardiac transplantation (P < 0.001). Patients with lower FT3 exhibited poorer long-term outcomes, with RCS identifying a critical threshold of 2.885 pg/ml (P-non-linear < 0.05).ConclusionsFT3 is a robust prognostic marker in HCM-HFpEF patients, supporting its integration into risk stratification. Clinicians should monitor FT3 levels, though intervention efficacy requires further prospective validation.
ISSN:2297-055X

Similar Items